These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6734036)

  • 61. Encainide disposition in patients with chronic cirrhosis.
    Bergstrand RH; Wang T; Roden DM; Avant GR; Sutton WW; Siddoway LA; Wolfenden H; Woosley RL; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1986 Aug; 40(2):148-54. PubMed ID: 3089668
    [TBL] [Abstract][Full Text] [Related]  

  • 62. High doses of spironolactone (Aldactone, SC-14266, Verospirone) alone and in combination with triamterene and-or diuretics in the treatment of refractory edema associated with secondary hyperaldosteronism.
    Radó JP; Marosi J; Takó J
    Endokrinologie; 1970; 57(1):46-62. PubMed ID: 4923990
    [No Abstract]   [Full Text] [Related]  

  • 63. [On the bioavailability of hydrochlorothiazide and triamterene from commercial drugs (author's transl)].
    Knauf H; Möhrke W; Mutschler E; Völger KD
    Arzneimittelforschung; 1980; 30(6):1001-4. PubMed ID: 7191258
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Metabolism of triamterene in the rat.
    Kau ST; Sastry BV; Alvin JD; Bush MT
    Drug Metab Dispos; 1975; 3(5):345-51. PubMed ID: 241615
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Normal metabolism of morphine in cirrhosis.
    Patwardhan RV; Johnson RF; Hoyumpa A; Sheehan JJ; Desmond PV; Wilkinson GR; Branch RA; Schenker S
    Gastroenterology; 1981 Dec; 81(6):1006-11. PubMed ID: 7286578
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Oral disposition kinetics of ofloxacin in patients with compensated liver cirrhosis.
    Orlando R; Sawadogo A; Miglioli PA; Cappellazzo MG; Palatini P
    Chemotherapy; 1992; 38(1):1-6. PubMed ID: 1617997
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effects of liver disease on the disposition of ciramadol in humans.
    Hoyumpa AM; Brown MW; Johnson R; Troxell R; Snowdy P; Schenker S
    J Clin Pharmacol; 1989 Mar; 29(3):217-24. PubMed ID: 2723108
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [STUDY OF THE URINARY ELIMINATION AND BLOOD PASSAGE OF TRIAMTERENE].
    BADINAND A; RONDELET J; VALLON JJ; CHAPPUIS O
    J Med Lyon; 1964 Jan; 45():101-12. PubMed ID: 14113136
    [No Abstract]   [Full Text] [Related]  

  • 69. [OBSERVATIONS ON THE CLINICAL USE OF TRIAMTERENE IN TREATMENT OF THE ASCITES OF HEPATIC CIRRHOSIS].
    BORRELLI PL; CAIRELLA M; DEMARTIIS M
    Clin Ter; 1964 Jun; 29():471-5. PubMed ID: 14173216
    [No Abstract]   [Full Text] [Related]  

  • 70. [Comparison of the cardiac effects of triamterene and its phase II metabolite p-hydroxytriamterene sulphuric acid ester (author's transl].
    Greeff K; Schuhmacher P
    Arzneimittelforschung; 1979; 29(4):705-6. PubMed ID: 582773
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Triamterene in the depletive treatment of cirrhosis].
    Ravenni G; Rubegni M; Forconi S
    Boll Soc Ital Biol Sper; 1964 Apr; 40(7):290-3. PubMed ID: 5875781
    [No Abstract]   [Full Text] [Related]  

  • 72. [Studies on the possible correlations between in vitro and in vivo data using commercial triamterene formulations (author's transl)].
    Stüber W; Mutschler E; Steinbach D
    Arzneimittelforschung; 1980; 30(7):1158-63. PubMed ID: 7191300
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of H2 antagonists on the differential secretion of triamterene and its sulfate conjugate metabolite by the isolated perfused rat kidney.
    Muirhead MR; Somogyi AA
    Drug Metab Dispos; 1991; 19(2):312-6. PubMed ID: 1676629
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Effect of the diuretics bemetizide and triamterene on renal excretion of potassium and sodium. Animal experiments].
    Neumann D; Haase W
    Med Welt; 1977 Oct; 28(40):1621-3. PubMed ID: 927120
    [No Abstract]   [Full Text] [Related]  

  • 75. [Pharmacokinetics of xipamide and triamterene in healthy probands].
    Diembeck W; Dies R; Heinz N
    Arzneimittelforschung; 1982; 32(11):1482-5. PubMed ID: 6891256
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The true composition of kidney stones passed during triamterene therapy.
    Sörgel F; Ettinger B; Benet LZ
    J Urol; 1985 Nov; 134(5):871-3. PubMed ID: 4057369
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pharmacokinetics of ciprofloxacin in liver cirrhosis.
    Ruhnke M; Trautmann M; Borner K; Hopfenmüller W
    Chemotherapy; 1990; 36(6):385-91. PubMed ID: 2292201
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Treatment of liver disease with malotilate. A pharmacokinetic and pharmacodynamic phase II study in cirrhosis.
    Bührer M; Le Cotonnec JY; Wermeille M; Bircher J
    Eur J Clin Pharmacol; 1986; 30(4):407-16. PubMed ID: 3743616
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease.
    Klotz U; Antonin KH; Brügel H; Bieck PR
    Clin Pharmacol Ther; 1977 Apr; 21(4):430-6. PubMed ID: 321178
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [EFFECT OF TRIAMTERENE ALONE AND COMBINED WITH BENZOTHIADIAZINE IN THE TREATMENT OF THE ASCITES OF HEPATIC CIRRHOSIS].
    GOMEZ R; ORELLANAALCALDE JM
    Rev Med Chil; 1964 Oct; 92():778-83. PubMed ID: 14273921
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.